CAS NO: | 1800046-95-0 |
生物活性 | Lanraplenib (GS-9876) is a highly selective and orally activeSYKinhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibitsSYKactivity in platelets via theglycoproteinVI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3]. | ||||||||||||||||
IC50& Target | IC50: 9.5 nM (SYK)[1] | ||||||||||||||||
体外研究 (In Vitro) | Lanraplenib (GS-9876) inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50values of 24-51 nM. Lanraplenib (GS-9876) inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, Lanraplenib (GS-9876) inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively)[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 443.50 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C23H25N9O | ||||||||||||||||
CAS 号 | 1800046-95-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 20 mg/mL(45.10 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |